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1.1 Colorectal cancer 
Colon cancer (CC) and rectum cancer (RC) are uniformly named as colorectal cancer (CRC). These 
diseases are originated from the large bowel and sharing some pathomorphological and molecular 
features as well as similar risk factors. 
1.1.1 CRC diagnosis 
The signs and symptoms related to CRC diagnosis can be very diverse and non-specific. Patients 
with early-stage CRC are usually asymptomatic, and found through general screening. Obstructive 
symptoms and changes in bowel habits possibly occur in tumors of the transverse and descending 
colon. Bleeding is the most common symptom of RC [1, 2].  
Colonoscopy is the first choice for the diagnosis of CRC. It is relatively easy to identify for advanced 
lesions, but not for early CRC. In order to ensure that these lesions are detected, complete mucosal 
examination and optimal bowel preparation are required [1, 3, 4]. 
Computed Tomography colonography is used as a complementary imaging method to diagnose 





Pathology is still the basis of pathological staging and follow-up management. In addition to the 
classic TNM staging, histological classification, grading and histological evaluation of lymphatic, 
perineural and venous infiltration, histology also is used to check increasingly important 
tumor-markers such as mismatch repair tests and specific mutations [1, 6-8]. 
Moreover, laboratory analysis is also necessary; the guidelines recommend checking the 
concentration of carcinoembryonic antigen at the time of diagnosis [9]. Increased baseline 
carcinoembryonic antigen concentration is associated with poor prognosis, or failure of return to 
normal status within a period of time after surgery may indicate residual disease [1]. 
1.1.2 CRC epidemiology 
In global cancer, the recent cancer statistics in 2020 presented that 1,931,590 individuals for both 
genders and all ages combined were diagnosed with CRC, and 935,173 patients with CRC died from 





Figure 1. (A) Estimated number of new cancer cases for both sexes and all ages in 2020, worldwide; (B) Estimated 
number of deaths from cancers for both sexes and all ages in 2020, worldwide. Data source: Globocan 2020; Graph 
production: Global cancer observatory (http://gco.iarc.fr).  
The 5-year prevalent cases of CRC were 5,253,335 with a proportion of 10.4% ranking second in all 
solid tumors. Among which Asia cases accounted approximately 50.0% (2,622,900 cases), followed 
by 29.2% Europe (1,536,168 cases) and 10.6% Northern America (554,680 cases) (Figure 2).  
Figure 2. (A) Estimated number of 5-year prevalent cancer cases for both sexes and all ages in 2020, worldwide; (B) 
Estimated number of cases with CRC in different areas of world for both sexes and all ages in 2020. Data source: 
Globocan 2020; Graph production: Global cancer observatory (http://gco.iarc.fr). 
In more detail, when describing at a national level, the global prevalence of CRC in 2020 was 
generally 67.4 per 100,000 with a range from 361.9/100,000 in Japan to 2.4/100,000 in Guinea. 
However, the highest prevalence of CRC was generally observed in Europe with the biggest rate of 
205.1 per 100,000, Northern America secondly (150.4/100,000), closely followed by Oceania 
(148.9/100,000), then Asia (56.5/100,000), Latin America and the Caribbean (52.9/100,000) as well 
as Africa (9.7/100,000) (Figure 3). The burden in the prevalence of CRC in Western countries could 





use, smoking as well as insufficient physical activity). In addition, a larger number of CRC occurred 
in Asia, to a large extent this phenomenon may possibly be attributable to the increasing trend of 
becoming westernized.  
 
Figure 3. Estimated number of 5-year prevalent cases as a proportion in CRC for both sexes and all ages in 2020, 
worldwide; Data source: Globocan 2020; Graph production: Global cancer observatory (http://gco.iarc.fr). 
1.1.3 Risk factors of CRC  
The global burden of CRC is possible contributed to the following categories (Figure 4). Generally, 
the risk factors of CRC are classified as hereditary and environmental factors. Most environmental 
risk factors for CRC could be modified by changes in lifestyle, especially in diet. As reported [10-19], 
established risks for CRC include cigarette smoking, high intake of red, processed meat, obesity, lack 




dairy products, tree nuts as well as foods containing dietary fiber, calcium and vitamin supplements 
have been found to protect from CRC.  
Besides, based on the epidemiological statistics, the male gender or/and elders more frequently 
develop CRC [20]. Also, individuals with type 2 diabetes show an elevated risk of CRC development 
because of shared risk factors for both diabetes and CRC [21, 22].  
 
Figure 4. List of modifiable and non-modifiable risk factors for CRC [10]. NSAIDs: non-steroidal 
anti-inflammatory drugs. 
On the other hand, genetic factors also play an important role in the development of CRC. The 
relative risk of CRC incidence varies from 0.89 to around 20-fold with the risk level from people 
without family history to people with inherited syndromes and a rising burden of family history. 




same positive family history at an elder age, people with positive family history at a younger age 
have a higher relative risk of CRC development [10, 23]. However, most genetic factors are still 
elusive and need to be further studied [24]. 
Hereditary syndromes of CRC are clinically divided into polyposis syndromes and non-polyposis 
syndromes (lynch syndromes) based on presence or absence of numerous polyps (Figure 5).  
Polyposis-related syndromes can be distinguished based on the histological type of polyps, their 
frequency of occurrence, the extent of extracolonic cancer as well as other clinical manifestations 
[25]. Patients with ten or more colon adenomatous polyps or two or more hamartomata’s polyps 
usually are considered as hereditary polyposis syndrome and referral for genetic assessment is given. 
In addition, hereditary polyposis syndromes should be taken into diagnostic account for patients with 
polyps in other parts of the gastrointestinal tract, in younger individuals with a family history as well 
as patients with various gastrointestinal cancers. In general, combining comprehensive clinical 
evaluation, family history inquiry, polyp pathology and pathogenic gene germline testing could be 
used to determine this specific situation [26-28]. 
Lynch syndrome, an autosomal dominant genetic disease, is associated with a high risk of 
gastrointestinal cancer such as CRC, stomach cancer as well as small intestine cancer. Lynch 
syndrome is responsible for around 6% of CRC [29], is caused by germline mutations in the DNA 
mismatch repair (MMR) genes MutL homolog 1 (MLH1) [30], MutS homolog 2 (MSH2) [31], MutS 
homolog 6 (MSH6) [32], post meiotic segregation increased 2 [33] and the epithelial cell adhesion 




mismatches occur particularly in microsatellites, which is known as microsatellite instability (MSI). 
In terms of functionality, the loss of MMR genes will lead to an accumulation of unfixed errors. 
Subsequently, this leads to the formation of adenomas and cancer [35]. 
 
Figure 5. The flow chart of CRC in polyposis or non-polyposis syndromes describing the core gene of familial 
CRC and polyposis genetic testing (Bule box); the unclear genetic explanation for the significant proportion of the 
polyposis and non-polyposis associated CRC phenotypes (Gray box); novel genes identified (POLE, POLD1, 
NTHL1, MSH3, and RNF43) or CRC susceptibility genes related to differing phenotypes (MUTYH; Purple box). 
Dotted lines mean the cases without clear genetic origin. CS, Cowden syndrome; FAP, Familial adenomatous 
polyposis; HMPS, Hereditary mixed polyposis syndrome; JPS, Juvenile polyposis syndrome; MAP, 
MUTYH-associated polyposis; MMR, Mismatch repair; PJS, Peutz-Jeghers syndrome; FCCTX, Familial 




1.1.4 CRC progression  
The development of CRC is related to several genetic and phenotypic changes in normal intestinal 
epithelial structure and function, leading to cell growth, proliferation as well as tumor progression. 
Since most CRCs are sporadic, rather than hereditary or familial, it is necessary to make efforts to 
explore these alterations, and to further improve the detection and treatments of CRC by identifying 
these changes. The sequence of adenoma-to-carcinoma during the tumor development reflects the 
accumulation of mutations in the colonic epithelium, which gives a selective growth advantage to the 
affected cells. These mutations occur at an early stage, usually in sporadic cases of adenoma and 
CRC. Somatic mutations must occur in multiple genes to form malignant transformation.  
The process of transformation from adenoma to carcinoma is given in Figure 6. Briefly, the genetic 
model of colorectal tumorigenesis involved genomic instability, oncogene pathway activation, 
mutational inactivation or loss of tumor suppressor genes, and growth factor pathway activation [36].  
Genomic instability includes three major molecular pathways which have been described for the 
progression of CRC: chromosomal instability (CIN) which causes changes in chromosome structure 
and copy number; MSI, which is initiated by aberrant DNA methylation or MMR gene mutations as 
well as CpG island methylator phenotype (CIMP) which is characterized by hypermethylation of a 
group of multiple genes [37-39]. 
Mutation or loss of APC, a tumor suppressor gene leads to the inappropriate activation of the Wnt 
signaling pathway, a mediator of the cell cycle, proliferation, and differentiation. In addition, 




DNA repair, and failure of apoptosis induction. More seriously, inactivation of the transforming 
growth factor-β (TGF-β) signaling pathway could promote the adenoma transformation into a 
higher-grade dysplasia or carcinoma, and it also inactivates SMAD4. Besides, mutations of Ras gene 
family members (KRAS, HRAS, and NRAS) plus BRAF will stimulate cell proliferation and other 
activities that promote carcinogenesis by activating the mitogen-activated protein kinase (MAPK) 
signaling pathway [40, 41]. Moreover, mutations in PIK3CA and PTEN are related to disturbed 
PI3K signaling pathway, and also have an effect on cell growth, proliferation, and survival [42]. 
 
Figure 6. The genetic changes associated with progression of CRC from adenoma to carcinoma 
(https://basicmedicalkey.com/colorectal-cancer-2/).   
The key growth factor pathways have been shown at the bottom of Figure 6. Activation of 




step of the transformation process from adenoma to carcinoma. Further, most of CRC lost the 
15-prostaglandin dehydrogenase (15-PGDH) which is responsible for degradation of prostaglandin. 
In addition, epidermal growth factor receptor (EGFR) is over-expressed or dysregulated in many 
human carcinomas including CRC [43], which influences cell growth, cell proliferation, 
differentiation, and angiogenesis. The activation of EGFR inhibits the mitogen-activated protein 
kinase (MAPK), PI3K as well as AKT signaling pathways, thus subsequently triggers colorectal 
tumorigenesis [36]. 
1.1.5 CRC prognosis 
Nowadays, the entire prognosis of CRC patients has been improved by early detection as well as 
advances in therapeutic strategies [44]. Generally, the standard treatment for CRC includes surgery 
alone for patients with localized and low-risk regional tumor; surgery + adjuvant 5-FU-based 
chemotherapy for patients with high-risk regional tumor and surgery + a variety of chemotherapies + 
targeted treatment for patients with distant metastatic tumor. However, compared to the patients 
diagnosed in localized disease, those patients who have distant metastasis still show a very poor 
5-year relative survival rate; around 90% vs. 14% [45].  
The prognosis of CRC is based on a variety of factors, even the specific tumor stage is a very 
significant prognostic factor, but not sufficient to make an advanced treatment decision. Currently, 
the identification and definition of molecular and genetic markers let more patients with CRC benefit 
since it allows to choose an optimal therapy regimen for specific CRC subgroups. A majority of 




prognosis when compared to those with microsatellite stability (MSS) or proficient MMR, especially 
for patients diagnosed in stages II and III colon cancer [46-49]. However, these patients with MSI 
cancer in stage II or stage III failed to show a favorable outcome after adjuvant chemotherapy with 
fluorouracil-based regimens [48, 50, 51].  
Moreover, a clinical trial for patients with stage III colon cancer, based on the detection of mutations 
in BRAF (V600E) or KRAS as well as MMR status, showed that patients with proficient MMR plus 
BRAF/KRAS mutations had significantly shorter survival outcome compared to those patients 
lacking these mutations [49]. Similar prognostic outcome was also observed in a majority of clinical 
trials [52-56]. These clinical trials suggested that MMR, BRAF and KRAS status could be 
considered as predictive genomic biomarkers for prognosis of CRC patients and subsequently taken 
into account for the guideline of the adjuvant setting [57].  
APC is most frequently mutated in CRC, however, its prognostic and predictive ability remains 
inconsistent [57]. A retrospective study reported that status of APC did not affect survival outcome 
in CRC patients [58]. However, Wang et al. [59] reported that patients with APC wild type overall 
survive shorter than those with mutant APC in MSS metastatic CRC (mCRC), regardless of the RAS 
and BRAF status. On the contrary, liver mCRC patients with double mutations of APC and PIK3CA 
were associated with inferior response to preoperative chemotherapy and worse survival outcome 
when compared to patients without mutations [60].  
The predictive ability of PIK3CA alone for prognosis is not clear, neither. Double mutations of 




receiving 5-fluorouracil-based therapies [61]. Some studies reported that aspirin use could decrease 
the total mortality for CRC cases with mutant PIK3CA, but not for those with wild-type PIK3CA 
[62-64]. However, contrary to the original hypothesis, in a study using a large number of patients, it 
was observed that regular aspirin use doesn’t significantly improve survival for PIK3CA-mutated 
CRC patients [65, 66].  
Furthermore, conflicting results were obtained in several studies concerning the role of TP53 for 
survival prediction in CRC. Some studies reported that CRC patients with mutant TP53 have a poor 
survival outcome [67, 68] and seem not to benefit from chemotherapies [69]. However, Kandioler et 
al. [70] presented that mutant TP53 was significantly associated with a good prognosis in CRC 
patients with N1 treated by adjuvant 5-FU-based chemotherapy, whereas no prognostic significance 
was seen in CRC patients with N2 tumors. On the other hand, other studies found that TP53 
mutations did not have an effect on survival outcome of CRC patients [58, 71-73]. Therefore, 
mutations of TP53, APC as well as PIK3CA, cannot be defined as prognostic and predictive 






Curcumin, a yellow coloring agent, is a phytochemical derived from Curcuma longa (turmeric) 
which belongs to the ginger family [74, 75] (Figure 7). In terms of chemical characteristics, the 
molecular formula of curcumin is C21H20O6 , with a molecular weight of 368.4g/mol and a melting 
point of 183 °C. Curcumin is insoluble in water as a condition of acidic and neutral pH, but soluble 
in ketone, alkali, acetic acid, chloroform as well as dimethyl sulfoxide [74, 76]. 
Figure 7. The molecular structure of curcumin isolated from the root of turmeric [75]. 
Curcumin was firstly isolated by Vogel in 1815 and its chemical structure was defined by V. Lampe 
and J. Milobedzka (Germany) in 1920. Commercially available curcumin also includes respectively 
17% and 3% of demethoxycurcumin (DMC) and bisdemethoxycurcumin (BDMC) [76, 77].  
Curcumin is usually utilized as an element of dietary supplements, a component of cosmetics, and a 




importantly, curcumin also is widely applicated in the field of medicine. For example, traditional 
Chinese medicine with a long history of over 2000 years includes various forms of herbal medicine 
[78], curcumin as well as its active derivatives is one of the most important medicine and used as a 
novel therapeutic agents for multiple diseases, such as cardiovascular disease [78-81], metabolic 
disorders [82, 83], rheumatic autoimmune diseases [84], neurological disease [76, 85-87], skin 
diseases [88] [89] as well as neoplastic disease [90-92] (Figure 8). 
 
Figure 8. Turmeric/curcumin shows pivotal role in the prevention of diseases including cancer [93]. 
The majority of studies indicated that curcumin has potential in both prevention and treatment of 
cancers. Curcumin has been well shown to suppress the cellular transformation, initiation, promotion 
and/or progression, invasion and metastasis [94, 95]. The studies used orthotopic / xenotransplant 
models and employed curcumin alone / curcumin in combination with existing current therapies. In 
rodents, curcumin was used for the treatment of transplanted human cancers such as, prostate [96, 
97], breast [98, 99], colon and rectum [100-102], ovary [103], lung [104], pancreas [105, 106], 




1.3 CRC and curcumin 
1.3.1 Functions in vitro 
In summary, curcumin has been reported as an agent for CRC in vitro, which is able to inhibit 
growth [110-113], accelerate apoptosis [111, 113, 114], make cell cycle arrest in G2/M stage [112, 
115] as well as suppress cell migration and invasion [110, 112, 116].  
Curcumin was found to act on various signaling pathways as well as molecular targets, such as 
enzymes COX-2, transcription factors (nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) and beta-catenin), Bcl-2 family members (Bcl-2, Bax, and Bcl-xL), death receptors (death 
receptor 5 (DR5) and Fas), protease enzymes (caspase 3 and caspase 8), and also reactive oxygen 
species (ROS) [100] (Figure 9). 
In detail, compared to the paired adjacent normal colorectal mucosa, the COX-2 is over-expressed in 
most of CRC and it has even been suggested as a potential biomarker for CRC [117]. Moreover, 
several studies [116, 118] reported that patients with COX-2 positive CRC have a poorer prognosis, 
compared to those with COX-2 negative CRC. However, Zhou et al. [119] and Kunnumakkara et al. 
[113] found that curcumin has an effect on the antitumor and anti-metastatic activity by inhibiting 
NF-κB activation itself as well as NF-κB-regulated gene expression including cyclin D1, Bcl-2, 
Bcl-xL, COX-2 and MMP-9. In addition, Chen et al. [120] reported that curcumin inhibited the 




of Early growth response protein 1 (Egr-1). On the other hand, curcumin can increase TP53 
expression and consequently speed up the apoptosis of CRC [114, 121] (Figure 9).  
 
Figure 9. Schematic representation of curcumin impact on multiple signaling pathways in cancers [122]. 
In fact, most of the anti-inflammatory and -tumor properties of curcumin are considered to be mainly 
block the NF-κB pathway activation, which has been investigated to be up-regulated in CRC 
representing a major cause for drug resistance [123, 124].  
At this time, chemotherapy is regarded as the basis of treatment and improves the prognosis for 
mCRC by multiple iterations of two or three chemo-drugs regimens. However, development of drug 
resistance is still a remarkable challenge [125-127], hence the exploration for more effective drugs 
always needs to continue. Porras et al. [128] reported that hyper-activated NF-κB in CRC cell lines is 
associated with resistance to oxaliplatin, and further determined the synergistic effect of oxaliplatin 
and curcumin in cell lines with acquired resistance to oxaliplatin. The most possible explanation is 




phenotype [128]. This phenomenon was continuously seen in the combination of conventional 5-FU 
and curcumin which led to more therapy effects against chemo-resistant CRC cells. It might also 
involve down-regulated NF-κB gene products via the NF-κB/PI-3K/Src pathway [129]. Moreover, 
curcumin was also found to block radiation-induced NF-κB activation thereby potentiating the 
antitumor effects of radiation therapy [130]. 
1.3.2 Functions in vivo and clinical trials 
In an animal model, Perkins et al., [131] in 2002, demonstrated that an intake of curcumin at 0.2%, 
which corresponded to 300mg/kg, prevented or delayed adenoma development. In detail, this study 
used C57BL/6J Min/+ (ApcMin/+) mice as a model for human familial adenomatous polyposis. 
These mice received a standard diet with curcumin concentrations of 0.1%, 0.2% and 0.5% for 15 
weeks. The 0.1% group did not show any effect, whereas the higher concentrations of 0.2% and 0.5% 
reduced the intestinal tumor number significantly by 39% and 40%, respectively [131].  
A phase I clinical trial [132] included 15 advanced CRC cases who were resistant to standard 
chemotherapies. Oral curcumin was used to replace the classical chemo-drugs by consuming 
capsules with curcumin leading to doses between 0.45 and 3.6g daily for up to 4 months. 
Dose-limiting toxicity was not observed. Curcumin and its glucuronic acid and sulfate metabolites 
were detected in plasma and urine at a concentration of 10nmol/L. PGE(2) was used as a biomarker 
of the potential activity of curcumin and measured in blood leukocytes of patients on days 1 and 29. 
The results showed that daily dosing of curcumin at 3.6g engendered 62% and 57% decreases in 




observed immediately pre-dose [132]. However, an early clinical study using human volunteers 
reported that the curcumin serum concentration 1 hour post-administration of 2g curcumin alone was 
very low (less than10 ng/ml), even undetectable [133]. Moreover, Wong et al. [134] reported that the 
serum curcumin concentration is only in the nanomolar range, indicating poor absorption and low 
bioavailability; consequently limiting its clinical potential. 
1.3.3 Development of curcumin nano-formulations and novel formulations 
As a result, this issue gives impetus to the development of curcumin nano-formulations and novel 
curcumin formulations in the quest of improving curcumin bioavailability in cancer. An example is 
Meriva®, a novel curcumin formulation, which displayed clear efficacy in a xenograft model. The 
combination of Meriva® plus oxaliplatin was better than Meriva® alone, followed by oxaliplatin and 
the control. The decrease in tumor volume when compared to vehicle-treated animals was 53%, 35% 
and 16%, respectively for the treatments. Addition of formulated curcumin to oxaliplatin-based 
chemotherapy regimens has the potential for clinical benefit [135]. Some clinical trials using novel 
curcumin formulations are ongoing with the goal to evaluate safety and efficacy in CRC prevention 
and treatment (shown in Table 1).  
Moreover, co-administration of 2g curcumin and 20mg piperine resulted in a remarkable 2,000% 
increase in oral bioavailability. It means that piperine has the ability to alter the metabolism of 
curcumin by blocking the glucuronidation process in the liver and intestine, therewithal significantly 
improve the curcumin oral bioavailability [133]. Besides, other promising oral drug delivery systems 




micelles, phospholipid complexes, microemulsions, nanoemulsions, emulsions, solid lipid 
nanoparticles, nano structured lipid carriers, biopolymer nanoparticles and microgels [123, 136, 137]. 
Table 1. Summary of ongoing clinical trials with bioavailable curcumin formulations in CRC [123].  
 
In summary, these data suggest that therapeutic curcumin use seems to be safe in humans, thus the 
design and development of new clinical trials focused on novel curcumin formulations as well as 





1.4 Aim of the study  
Improving clinical application should not only focus on curcumin bioavailability, but also on the 
identification of specific CRC subsets with best sensitivity to curcumin.  
It is also noteworthy to mention, that different CRC cell lines responded to treatments differently, 
possibly due to genomic instability or phenotypic changes [122]. I hypothesized that also the 
sensitivity to curcumin might be linked to specific molecular features such as MSI status, mutations 
or certain activated molecular signaling pathways. 
Therefore, the present study aimed at 1) testing the sensitivity of CRC cell lines with defined 
molecular alterations to curcumin; 2) mechanistically analyzing sensitive CRC cell lines in order to 
identify the mode-of-action; 3) identifying biomarkers associated with curcumin sensitivity; 4) 
establishing a predictive model using biomarkers to predict the sensitivity of additional CRC cell line 
to curcumin.    
MATERIALS AND METHODS  
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BD FACS Calibur Becton Dickinson, Heidelberg, Germany 
Centrifuge 5415 D Eppendorf, Hamburg, Germany 
Centrifuge Rotina 420 R Hettich, Tuttlingen, Germany 
Freezer (-20℃) Bosch and Kryotech, Germany 
Freezer (-80℃) Bosch and Kryotech, Germany 
Fridge (4℃) Liebherr, Germany 
Heater HBT-1-131 Heap Labor Consult, Bovenden, Germany 
Incubator Thermo Fisher Scientific, Waltham, USA 
Light microscope CKX 41 Olympus Deutschland, Germany 
Tecan Infinite M200 Microplate Reader TECAN, Hudson, USA 
Cellular Technology Ltd. ELISpot reader ImmunoSpot, USA 
Neubauer-counting chamber Marienfeld, Lauda Konigshofen, Germany 
Pipetboy Integra Bioscidence, Fernwald, Germany 
Vortex Genie 2 Scientific Industries, New York, USA 
MSC-Advantage Class Ⅱ Biological safety 
cabinets 
Thermo Fisher Scientific, Waltham, USA 
IKA digital 3D rocker Thermo Fisher Scientific, Waltham, USA 
Multi-stepper Eppendorf, Hamburg, Germany 
Brand Handystep Sigma, Germany 
Pipettes Eppendorf, Hamburg, Germany 
MATERIALS AND METHODS  
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2.1.2 Disposable products 
Disposable Products Manufacturers 
Cell culture flasks Greiner Bio-One, Kremsmünster, Austria 
Cell culture plates Greiner Bio-One, Kremsmünster, Austria 
Falcon tubes cellstar Greiner Bio-One, Kremsmünster, Austria 
FACS tubes Sarstedt, Nümbrechus, Germany 
Micro tubes Sarstedt, Nümbrechus, Germany 
Pipette tips Eppendorf, Germany 
Serological pipettes Greiner Bio-One, Kremsmünster, Austria 
Pasteur pipettes Thermo Fisher Scientific, Waltham, USA 
Dispenser tips TipOne, Germany 
2.1.3 Chemicals and Reagents 
Chemicals and Reagents Manufacturer 
Dulbecco's modified Eagle's medium 
(DMEM)/Ham's F-12 
Pan-Biotech, Aidenbach, Germany 
DMEM/Ham's F12 Capricorn Scientific GmbH, Germany 
L-glutamine Pan-Biotech, Aidenbach, Germany 
Dulbecco's phosphate buffered saline (DPBS) Pan-Biotech, Aidenbach, Germany 
Fetal bovine serum  Pan-Biotech, Aidenbach, Germany 
Trypsin/EDTA Pan-Biotech, Aidenbach, Germany 
70% Ethanol Apomix, Germany 
Fetal bovine serum  Pan-Biotech, Aidenbach, Germany 
4% Formafix Formafix GmbH, Düsseldrof, Germany 
Propidium iodide (PI) AppliChem, Darmstadt, Germany 
Trypan blue (0.02%) Sigma-Aldrich, Hamburg, Germany 
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Dimethyl sulfoxide (DMSO) AppliChem, Darmstadt, Germany 
Sodium chloride Carl Roth GmbH, Germany 
Potassium chloride MERCK, Germany 
Di-sodium hydrogen phosphate dihydrate MERCK, Germany 
Potassium di-hydrogen phosphate MERCK, Germany 
Saponin AppliChem, Darmstadt, Germany 
Ethanol absolute Walter CMP, Kiel Germany 
Sodiumdodecylsulfat (SDS) AppliChem, Darmstadt, Germany 
Natrum chorid (NaCL) Roth, Germany 
Tween 20 Sigma-Aldrich, Hamburg, Germany 
RNase Sigma-Aldrich, Hamburg, Germany 
HEPES Sigma-Aldrich, Germany 
PE anti-IκB-α BioLegend, Germany 
Annexin V Immuno Tools, Germany 
Curcumin Sigma-Aldrich, Germany 
2.1.4 Buffer and Medium 
Buffer and Medium Components 
Cell culture medium 
445ml DMEM/Ham's F12 medium; 50ml FBS; 
5ml L-glutamine  
Freezing medium 45ml serum; 5ml DMSO 
10 × PBS  
80g sodium chloride; 2g potassium chloride; 
18.05g di-sodium hydrogen phosphate dihydrate; 
2g potassium di-hydrogen phosphate; 1000ml 
dH2O; pH: 7.2 - 7.4 
100 × Buffer P 
0.5ml FBS; 5ml 1% Saponin; 5ml 0.1mol/l 
HEPES; 39.5ml 1 × PBS 
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10 × Binding buffer 
0.1mol/l HEPES; 1.4mol/l NaCl; 25mmol/l 
CaCl2•2H2O in distilled water 
Crystal violet (Final: 0.2%) 
200mg crystal violet; 2ml ethanol absolute (final 
2%); ad 100ml distilled water 
Sodiumdodecylsulfat (SDS, Final: 1%) 1g SDS; ad 100ml distilled water 
2.1.5 Patient consent 
After patient consent obtained, the primary samples were collected from the surgery. The further 
research was approved by the Ethics Committee of the University of Rostock (Reference number: Ⅱ 
HV 43/2004) based on guidelines for the use of human material. The present study included age, sex 
(male, female), tumor location (colon: right, transverse, left, sigmoid and rectum), T stage (T0, T1, 
T2, T3 and T4), N stage (N0, N1and N2), M stage (M0 and M1), UICC stage (Ⅰ, Ⅱ, Ⅲ and Ⅳ), grade 
(G1, G2, G3 and G4), mutations (APC, TP53, KRAS, BRAF, PIK3CA and ATM) and MSI status 
(MSI and MSS).   
2.1.6 CRC cell lines 
A large panel of low passage cell lines has been established in Molecular Oncology and 
Immunotherapy group, included CRC patient-derived / PDX-derived as well as primary / metastatic 
cell lines [138].  
Finally, 32 CRC cell lines were used in present study including 31 HROC cell lines and HHC6548.  
List of CRC cell lines in this cohort was shown in followed pictures. 




HROC18; T2N0M0; G2; UICC I 
 
 
HROC24; T2N0M0; G2; UICC I 
 
 
HROC32; T4N2M1; G2; UICC IV 
 
HROC39; T4N0M0; G3; UICC Ⅱ 
 
 
HROC43; T3N2M0; G3; UICC Ⅲ 
 
HROC50 T1 M5 (HROC50); 
T4N0M0; G2; UICC Ⅱ 
 
HROC57; T3N2M1; G3; UICC Ⅳ 
 
 
HROC60; T2N0M0; G2; UICC Ⅰ 
 
HROC69; T3N0M0; G3; UICC Ⅱ 
HROC80 T1 M1; T3N2M0; G2; 
UICC Ⅲ 
 
HROC87 T0 M2 (HROC87); 
T3N0M0; G3; UICC Ⅱ 
HROC113; T4bN2M0; G3; UICC Ⅲ 
HROC126; T3N1M0; G2; UICC Ⅲ 
 
HROC131; T3N1M0; G3; UICC Ⅲ HROC173; T4N2M1; G3; UICC Ⅳ 
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HROC183; T3N2M0; G3; UICC Ⅲ 
 
HROC212; T4N2M1b; G3; UICC Ⅳ HROC217; T3N1M0; G2; UICC Ⅲ 
HROC222; T3N0M0; G2; UICC Ⅱ 
 
HROC257; T4N2M0; G3; UICC Ⅲ HROC277 T0 M1 (HROC277); 
T4N0M1; G2: UICC Ⅳ 
HROC285 T0 M2 (HROC285); 
T4bN2M1; G2; UICC Ⅳ 
 
HROC296; T3N0M0; G2; UICC Ⅱ HROC300 T2 M1 (HROC300); 
T4N1M1; G2; UICC Ⅳ 
HROC309; T3N0M0; G2; UICC Ⅱ 
 
HROC315 T1 M2 (HROC315); 
T3N2bM0; G3; UICC Ⅲ 
HROC324; T3N2M1a; G3; UICC Ⅳ 
HROC348; T3N2M1; G3; UICC Ⅳ 
 
HROC357; T3N0M0; G2; UICC Ⅱ HROC370; T2N0M0; G2; UICC Ⅰ 




CRC patient-derived cell lines are named by starting with HROC (Hansestadt Rostock colorectal 
cancer) and patient ID number, for example HROC24; PDX-derived cell lines were additionally plus 
the number of passage in vivo (shown as Transfer: T) and the number of mice (shown as M), for 
example HROC24 T0 M1; besides, the mCRC cell lines both patient- and PDX-derived plus the 
“Met” closed by the patient ID number, such as HROC277Met and HROC277Met T0 M2 [138].  
These well-characterized and low-passage cell lines are comprehensive in comparison to the parental 
tumor by the morphology, phenotype, molecular characteristics, chemotherapeutic- and 
radiation-response. This biobank of CRC cells is considered as a useful tool for the future research 
on the biological characteristics and clinical studies [139-143]. 
 
HROC383; T3N0M0; G3; UICC Ⅰ 
 
 
HHC 6548 T1 M1 (HHC6548); 
T3N2Mx; G3; unclear UICC 
 




2.2.1 Establishment of patient derived- or PDX derived- cell lines 
In brief, the fresh tissues of CRC were obtained from clinical operation, immediately, these tissues 
were minced by the crossed scalpels in PBS, then passed through a cell strainer to collect some 
single cells. After washing using PBS, these cell pellets were seeded on 6-well plates with 
collagen-coated [138].  
2.2.2 Mutation and molecular subtype of CRC cell lines 
The information of mutations and MSI status has been previously performed. As described before, 
the mutational status was determined by testing of KRAS exon 2-4, BRAF exon 15, TP53 exon 5-8, 
APC exon 16, PIK3CA exon 10 and 21 [138, 144]. Molecular subtype was identified based on the 
research from Ostwald and colleagues on an ABI 3500 genetic analyzer (Applied biosystems, 
Darmstadt, Germany) [143-145]. 
2.2.3 Cell culture 
Cell culture was done under a sterile laminar flow hood. The CRC cell lines were quickly thawed, 
after a centrifugation at 1200rpm for 10 minutes, resuspended in 5ml medium containing 10% FCS 
and 2mM L-glutamine and cultured in the T25 culture flasks. The medium was changed every 3 - 4 
days. When the cells expand to an 80% confluence, subsequently, enzymatic cell detachment was 
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treated by trypsin. After an incubation time of 5 - 10 minutes at 37℃, the cell pellets were 
resuspended in a bigger T75 culture flask and grow in a humidified incubator (5% CO2 and 37℃) for 
the further research.  
The CRC cell lines lower than 50 passages were used in order to ensure the comparability of 
molecular characteristics between parental tumor and tumor-derived cell lines.  
Moreover, to avoid contamination, mycoplasma test was performed every 6 weeks in routine by a 
16S-rRNA gene-based PCR amplification from whole cell lysates. All cells used in present study 
showed negative results.  
2.2.4 Cell counting   
Cell counting was performed by trypan blue assay with the support of counting chamber. The trypan 
blue can discriminate the living cells from the dead cells by non-staining the nuclei of living cells. In 
present analysis, the mixture of 5μl cell suspension and 5μl trypan blue was loaded into the counting 
chamber. The cells from two squares of chamber were counted and calculated by this formulation: 
cell number / ml = (number of viable cells / numbers of the counted squares) × 2 × 104. 
2.2.5 Chemo-test and crystal violet 
1.0 × 104 - 1.5 × 104 CRC cells per well were seeded in a 96-well plate, and allowed to adhere for 24 
hours. Cultures were treated by changing the medium with the increasing concentrations of curcumin 
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(0μM, 1μM, 5μM, 10μM, 15μM, 20μM and 25μM) and incubated for 72 hours. Then, medium 
containing curcumin was changed and left for incubation of another 72 hours.  
After that, these cells were stained using crystal violet assay. In short, these cells after treatments 
were firstly washed using 100μl PBS, then added 50μl crystal violet solution per well, and incubated 
on a shaker for 15 minutes at room temperature. After that, the cells were washed twice, again. 
Photos were taken using the ELISpot reader after the cells were completely dried. These cells were 
quantified by adding 100μl 1% SDS per well and incubated on a shaker for 10 minutes at room 
temperature. Then the cells were measured by using the Tecan reader with an absorption at 570nm 
(reference: 620nm). Cell viability is calculated by the formula: cell viability = (sample – dead control) 
/ (living control – dead control) × 100%.   
2.2.6 Annexin V and propidium iodide staining 
2 × 105 CRC cells per well were harvested, put in a 6-well plate, and left for incubation overnight. 
These cells were treated by 5%FCS medium containing 0μM, 10μM, 15μM and 20μM curcumin for 
incubation of 72 hours. The cell death was evaluated by apoptosis assay with Annexin-V (Immuno 
Tools, Germany, cat: 31490013) and propidium iodide (PI, AppliChem, Germany, code: A2261) 
labeling. In brief, the cells were harvested and transferred into FACS tubes, washed by 500μl 1 × 
binding buffer. Cells were resuspended in 70μl 1 × binding buffer plus 5μl Annexin-V-FITC / 
non-Annexin-V-FITC by protected from light and incubated for 15 minutes at room temperature. 
After that, 400μl 1 × binding buffer was added in each tube. Finally, PI was just added within 1 
minute before measurement.  
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The cell death was determined by the formula: 100% - (Annexin V- PI-) %. 
2.2.7 Evaluation of inhibitors of NF-kappa-B (IκB) level in CRC cell lines 
5 × 105 CRC cells per well were seeded in a 6-well plate for incubation of 24 hours; then changed the 
medium and allowed cells to adhere for 24 hours. 
After that, the cell pellets were harvested and fixed using 400μl 2% FORMAFIX per tube for 15 
minutes at room temperature; washed by 400μl PBS followed by an incubation using 400μl 1 × 
buffer P for 10 minutes at room temperature. Next, the cell pellets were resuspended in 100μl 1 × 
buffer P with and without 5μl anti-IκB-α (BioLegend, Germany, Cat: 662412) by protected from 
light and incubated for 30 minutes at 4℃. The cell pellets per tube were washed again by 400μl 1 × 
buffer P and resuspended using 200μl 2% FORMAFIX per tube, then the IκB expression was 
measured by flow cytometry. 
2.2.8 Evaluation of IκB level in CRC cell lines after curcumin treatment 
5 × 105 CRC cells per well were seeded in a 6-well plate and left for incubation overnight; then 
changed medium by 5% FCS medium and 5% FCS medium containing 10μM, 15μM, 20μM 
curcumin and incubated of 24 hours. The procedure for measurement of IκB expression in 
pre-treated cells is same as evaluation of IκB level in CRC cell lines. 
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2.2.9 Cell cycle 
Curcumin pre-treated CRC cells were harvested, followed by a wash step using 2ml PBS, then 
resuspended in 1ml ice-cold 70% ethanol, vortexed, added 1ml ice-cold 70% ethanol again for more 
than 12 hours incubation at -20℃. After that cell pellets were washed again using 2ml PBS, 
resuspended in 300μl PBS containing 0.1% Tween 20 and 1mg/ml RNase and incubated at 4℃ for 1 
hour. The cell cycle was measured using the Cellquest program after adding 50μl 0.1mg/ml PI 
solution. 
2.2.10 Wound healing assay 
5 × 105 cells per well were seeded in a 6-well plate and incubated until reaching 100% confluency. 
Then the medium was changed by DMEM/Ham's F12 medium or containing 10μM curcumin, and 
incubated for 24 hours in a humidified incubator. Afterwards, the monolayers were scratched using a 
20μl pipette tip to generate a wound. Wounds were documented from day 0 to day 5 using a light 
microscope with a 4 × objective lens. Finally, the wounded diameter per day was measured to 
evaluate cell migration ability.  
2.3 Statistical analysis 
The cell viability at gradient concentrations of curcumin was shown by a heatmap visualization 
technique with support of TBtools software [146]. The correlation analysis of IκB and IC50 or IκB 
and cell viability was evaluated by Pearson or Spearman’s rank correlation (according to the data’s 
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normality or not) and presented as correlation coefficient (rs). The difference of IC50 between two 
different mutation status or MSI status was compared using student t-test, and presented as mean ± 
standard deviation (SD). However, the difference of IC50, cell death, IκB level after curcumin 
treatment, as well as cell cycle within ≥ 3 groups was compared using ANOVA analysis, similarly 
presented as mean ± SD. In addition, the migration ability between non-drug and curcumin treatment 
was analyzed by linear regression, and shown as slopes of regression line. The predictive ability for 
curcumin sensitivity was performed using Receiver Operating Characteristic (ROC) curve, and 
presented by the area under the ROC curve (AUC). 
P-values lower than 0.05 were considered significant. All experiments were independently repeated 
for at least three measurements. All statistical analyses were performed using GraphPad Prism 6.0 






3.1 Patients and tumor characteristics 
In general, 32 low-passage cell lines established from 30 CC patients and 2 RC patients were used in 
this study. CRC patients had a mean age of 66 years with a range from 26 to 98 years, and consisted 
of 15 males and 17 females. In detail, the patient and tumor data also include classification, 
molecular type as well as somatic mutations. The percentage of Union Internationale Contre le 
Cancer (UICC) stage was 40.63% for stage I - II and 56.25% for stage III - IV. After molecular 
diagnosis, around 60% of the study population were MSS and 40% MSI. Moreover, except 2 
untested tissues, 56.25% of all specimens were TP53 mutated; around 60% had an APC mutation; 
43.75% were K-Ras, 28.13% B-Raf, 15.62% PIK3CA as well as 12.50% ATM mutated (Table 2).  
Table 2. Patient characteristics 
Variables   n % 
Age (years) *   32 66.34 ± 17.85 
Gender male 15 46.88 
  female 17 53.13 
Sample location colon 30 93.75 
  rectum 2 6.25 
T stage T0-T2 4 12.50 
  T3-T4 28 87.50 
N stage N0 14 43.75 
  N1-2 18 56.25 
M stage M0 22 68.75 
  M1 9 28.13 
  Mx 1 3.13 
R stage R0 23 71.88 




  unclear 1 3.13 
L stage L0 21 65.63 
  L1 9 28.13 
  unclear 2 6.25 
V stage V0 19 59.38 
  V1-2 11 34.38 
  unclear 2 6.25 
UICC stage I-II 13 40.63 
 III-IV 18 56.25 
  unclear 1 3.13 
MSI status MSS 19 59.38 
  MSI 13 40.63 
TP53 wt 12 37.50 
  mut 18 56.25 
  unclear 2 6.25 
APC wt 11 34.38 
  mut 19 59.38 
  unclear 2 6.25 
K-Ras wt 16 50.00 
  mut 14 43.75 
  unclear 2 6.25 
B-Raf wt 21 65.63 
  mut 9 28.13 
  unclear 2 6.25 
PIK3CA wt 25 78.13 
  mut 5 15.62 
 unclear 2 6.25 
ATM wt 26 81.25 
  mut 4 12.50 
  unclear 2 6.25 
* age was presented as mean ± SD; wt, wild type; mut, mutant type. 




All CRC cell lines were treated with six concentrations of curcumin (1μM, 5μM, 10μM, 15μM, 
20μM and 25μM). A minority of CRC cell lines responded at a concentration of 5μM curcumin. In 
addition, nearly half of the tested CRC cell lines displayed around 50% cell viability after 10μM 
drug treatment. However, up to 20% CRC cell lines are still resistant to the highest drug 
concentration used (Figure 10).  
Figure 10. The 32 CRC cell lines were tested for curcumin sensitivity by a long-term proliferation assay. Each cell 





3.3 IC50 of curcumin and IκB level in CRC cells 
The IC50 of curcumin showed a range from 6.69μM to 18.49μM. This result identified the most 
sensitive five cell lines including the lowest IC50 of curcumin: HROC18 (IC50 = 6.69μM), closely 
followed by 6.97μM for HROC357, 7.02μM for HROC50, 7.60μM for HROC222 as well as 7.72μM 
for HROC126. On the contrary, the several top resistant cell lines were HROC24 with an IC50 of 





Figure 11. The IC50 of curcumin and the IκB expression level in CRC cell lines of the HROC collection. The IC50 
of curcumin was calculated with the support of GraphPad Prism 6 software. The IκB level in CRC cells was 
determined using flow cytometry. Blank group (grey histograms) represented staining with an irrelevant control 
antibody and the IκB group (red histograms) represented staining of IκB antibody; the bars were expressed as 
standard deviation (SD) of the mean.  
Next, the inhibitors of the IκB level in all 32 CRC cell lines were directly measured by flow 
cytometry. The IκB expression level in CRC cell lines differed from the highest value 56.96% to the 
lowest value of 3.2%. Interestingly, it has been found that the above mentioned most sensitive five 
cell lines had very high IκB levels with 56.96% in HROC126, 42.82% in HROC222, 39.72% in 
HROC50, 32.73% in HROC18 as well as 31.54% in the HROC357 cell line. On the other hand, the 
curcumin resistant cell lines expressed very low IκB levels, only 3.20% in HROC285, 3.43% in 
HROC24, 9.23% in HROC324 and 11.28% in the HROC87 cell line. Notably, a marked difference 
in IκB levels between sensitive and resistant CRC cell lines was observed in this analysis (Figure 
11). 
3.4 Correlation analysis between IC50 of curcumin and IκB in HROC cell lines 
In order to identify the correlation between IκB and IC50 of curcumin in CRC cell lines, a Pearson 
correlation analysis was performed. The correlation analysis showed that IC50 of curcumin in CRC 
cell lines was significantly negatively correlated with the level of IκB in cells, and with a 
coefficient of -0.72, P < 0.001 (Figure 12). This strongly proposed that CRC cell lines with high 
IκB levels are likely more sensitive to curcumin, conversely cell lines with lower IκB levels are 





Figure 12. The IC50 of curcumin correlates with IκB expression levels of CRC cell lines. This correlation analysis 
was performed by Pearson analysis, and the correlation coefficient (rs) was identified as the measurement of the 
strength of the relationship between IC50 of curcumin and IκB expression level in CRC cell lines.   
3.5 Genomic profiles and curcumin sensitivity in CRC cell lines 
Mutations in APC, K-Ras, B-Raf, PIK3CA, TP53 as well as ATM genes are commonly evaluated as 
biomarkers in CRC. In present study, the IC50 of curcumin was also analyzed based on mutant or 
wild type of APC, K-Ras, B-Raf, PIK3CA, TP53 as well as ATM, respectively, in CRC cell lines. 
Overall, these results showed that higher IC50 of curcumin were found in CRC cell lines with wild 
type in the genes APC, and with mutant status of the genes B-Raf, K-Ras, PIK3CA, TP53 as well as 
ATM (Figure 13). However, these mutational signatures did not significantly discriminate 




Figure 13. The IC50 (μM) of CRC cell lines to curcumin in cell lines with different mutational profiles for APC (A), 
K-Ras (B), B-Raf (C), PIK3CA (D), TP53 (E) and ATM (F). The t-test was performed to compare the mean value 




3.6 MSI status and curcumin sensitivity in CRC cell lines 
Stratified by MSI status, the IC50 of curcumin in MSS CRC cell lines is significantly lower than in 
MSI CRC (MSS vs. MSI, 10.50 ± 0.66μM vs. 13.67 ± 1.03μM, P = 0.011) (Figure 14A). This 
signified that CRC cell lines with MSS are more sensitive to curcumin, while CRC cell lines with 
MSI are less responding to curcumin. In addition, the IκB level in CRC cell lines was also compared 
by MSI status. Interestingly, the analysis showed that the mean IκB level in MSS CRC cell lines is 
significantly higher compared to MSI CRC cell lines (MSS vs. MSI, 25.37 ± 2.40μM vs. 14.91 ± 
2.72μM, P = 0.008) (Figure 14B).     
 
Figure 14. The comparison of IC50 (μM) of curcumin between MSI and MSS CRC cell lines (A). The comparison 




3.7 Prediction of a subset of CRC cell lines with sensitivity to curcumin 
According to MSI status and IκB level in cells, all CRC cell lines were further divided into three 
groups: MSS cell lines with high IκB level (High IκB_MSS), MSS cell lines with low IκB level or 
MSI cell lines with high IκB level (Low IκB_MSS or High IκB_MSI) as well as MSI cell lines with 
low IκB level (Low IκB_MSI). After pairwise comparisons, no difference between High IκB_MSS 
and Low IκB_MSS or High IκB_MSI was observed for IC50 of curcumin; but these two groups 
showed significantly lower IC50 compared with the Low IκB_MSI group, respectively. Therefore, 
both groups of High IκB_MSS and Low IκB_MSS or High IκB_MSI was combined as an entire one 





Figure 15. The IκB level in CRC cells and their MSI status were used to predict the CRC cell lines sensitivity to 
curcumin. The IC50 of curcumin were compared among CRC cell lines with High IκB_MSS, Low IκB_MSS or 
High IκB_MSI as well as Low IκB_MSI using multiple comparison of ANOVA (A). The predictive ability of IκB 
level in CRC cells and MSI status was evaluated by receiver operating characteristic (ROC) and presented by the 
area under the ROC curve (AUC) (B).  
In order to predict the curcumin sensitivity, all CRC cell lines were divided into a 
curcumin-resistance group and a curcumin-sensitivity group based on the median IC50 of curcumin 
(Figure 11). Then, IκB level and MSI status were used as the biomarkers to predict the sensitivity of 
CRC cell lines to curcumin.  
Finally, the AUC of ROC presented a significantly predictive value (AUC = 0.72, 95%CI: 0.54 - 
0.90, P = 0.035) with a 72% probability which could correctly distinguish curcumin sensitive CRC 
cell lines form those resistant ones (Figure 14B).  
3.8 Cell death after curcumin treatment 
In order to further examine the different sensitivity between High IκB or MSS group and Low 
IκB_MSI group, three cell lines from these two groups were respectively selected. HROC24, 
HROC113 and HROC285 cell lines with the features of Low IκB and MSI are regarded as the 
curcumin-resistance CRC cell lines. On the contrary, the HROC18, HROC357 and HROC69 cell 
lines with the characteristics of High IκB and MSS are considered as the curcumin-sensitivity CRC 




These cell lines were pre-treated using non-drug (control), 10μM curcumin, 15μM curcumin and 
20μM curcumin for 72 hours, then the difference between control and curcumin treatment was 
analyzed. As expected, cell death in HROC24, HROC113 and HROC285 was not significantly 
different in comparison to the controls, even at a concentration of 20μM curcumin. However, in the 
curcumin-sensitive group, cell death was significantly higher in all three cell lines compared to the 
control group (P < 0.05), even with an obvious positive dose response. The strong 
curcumin-response in HROC357 started at 10μM curcumin (P < 0.05), and the cell deaths in 







Figure 16. The cell death was measured in three curcumin-resistance CRC cell lines (HROC18, HROC69 and 
HROC357) and three curcumin-sensitivity CRC cell lines (HROC24, HROC285 and HROC113) after treating with 
10μM, 15μM, 20μM curcumin. The cell death of these cells was detected by flow cytometry. *, compared to 
control; #, compared to 10μM curcumin treatment; $, compared to 15μM curcumin treatment; all these markers 
showed P < 0.05. CUR, curcumin. 
3.9 Migration after curcumin treatment 
Two curcumin sensitive cell lines (HROC18 and HROC357) and two curcumin resistant cell lines 
(HROC24 and HROC87) were pre-treated by non-drug (control) and 10μM curcumin for incubation 
overnight, after that the wounded diameters were measured daily for up to 5 days. Similarly, 
compared to the controls, the migration in HROC24, HROC87 failed to show statistical significance. 
However, in the curcumin-sensitive group, the migration ability of cells after 10μM curcumin 





Figure 17. Migration test in two curcumin-resistant CRC cell lines (HROC24 and HROC87) and two 
curcumin-sensitive CRC cell lines (HROC18 and HROC357) treated by 10μM curcumin, for 24 hours. Migration 
was detected by wound healing assay. The statistical difference analysis was performed by linear regression, P＜




3.10 Cell cycle after curcumin treatment 
This present study also evaluated the cell cycle using two curcumin sensitive and two resistant CRC 
cell lines. After 72 hours treatment with 20μM curcumin, the data showed that curcumin made 
around 20% HROC24 and HROC285 cells arrest at the S stage (P < 0.05, Figure 18A and B), but 
more than 50% HROC69 and HROC357 cells arrested at the G2/M stage (P < 0.05, Figure 18C and 
D). 
 
Figure 18. Cell cycle in two curcumin-resistant CRC cell lines and two curcumin-sensitive CRC cell lines treated 
by 10, 15, 20μM curcumin. Cell cycle was detected by flow cytometry. *, compared to control (non-curcumin 




3.11 Increased IκB after curcumin treatment 
Curcumin-sensitive and -resistant cell lines were also incubated using non-drug (control), 10μM 
curcumin, 15μM curcumin and 20μM curcumin for 24 hours, then the IκB level in cells was detected. 
In general, a growing trend of IκB was observed in all these 6 CRC cell lines with increasing 
curcumin concentrations. The IκB level in curcumin-resistant cell lines is significantly lower in the 
non-drug treatment group (compare Figure 19 A, B and C to D, E and F). After treatment with 20μM 
curcumin only around 20% increase in IκB (P < 0.05, Figure 19A-C) could be detected. However, 
for the sensitive cell lines, a significant difference between control and curcumin treatments starts at 
10μM curcumin (P < 0.05), with even up to 70% increase of IκB triggered by 20μM curcumin (P < 






Figure 19. The IκB level in three curcumin-resistant and three curcumin-sensitive CRC cell lines treated by 10μM, 
15μM, 20μM curcumin. IκB level of these cells were detected by flow cytometry. *, compared to Blank; #, 
compared to control (CTRL); $, compared to 10μM curcumin treatment; all these markers mean P < 0.05. CUR, 
curcumin. 
3.12 Correlation analysis between cell viability and IκB after curcumin treatment 
After curcumin treatment (10μM, 15μM and 20μM, respectively), the correlation analyses between 
cell viability and increased IκB levels were done in 6 CRC cell lines (three curcumin resistant cell 
lines: HROC24, HROC113 and HROC285; three curcumin sensitive cell lines: HROC18, HROC69 
and HROC357). At first, with 10μM curcumin treatment, a strongly significant correlation between 
cell viability and IκB level in CRC cell lines was observed (Figure 20A), with a very high value of 
coefficient (rs = -0.943, P = 0.017). This means that the cell viability is negatively associated with 




correlation continued to show with 15μM (Figure 20B; rs = -0.986 (P < 0.0001)) and 20μM 
curcumin (Figure 20C; rs = -0.928 (P = 0.006)) groups.  
 
Figure 20. Correlation analysis of cell viability and IκB after treatment with 10μM (A), 15μM (B) and 20μM (C) 






The present study is the first report screening a subset of CRC cell lines with sensitivity to curcumin 
and identified a possible biomarker which is associated with the curcumin sensitivity in CRC cell 
lines. In detail, 32 CRC cell lines were stratified for MSI status, APC, K-Ras, B-Raf, PIK3CA, TP53 
and ATM mutations, and tested sensitivity to curcumin. In the preliminary sensitivity test, it was 
found that CRC cell lines of this panel have different sensitivities to curcumin.  
In the next exploration for a biomarker of curcumin sensitivity, and taking into account that 
mutations in APC, K-Ras, B-Raf, PIK3CA, TP53 and ATM are usually considered as relevant CRC 
biomarkers [147-153], the difference between wild type and mutations of these genes was compared 
in the different cell lines, but mutations in these genes were not associated with curcumin sensitivity 
or resistance.  
Moreover, MSI status or MMR genes was also regarded as an important biomarker in cancer 
progression, prognostic outcome, even adjustment of adjuvant chemotherapy [154-157]. In this case, 
analyzing the curcumin sensitivity stratified by MSI status seems necessary. This result showed that 
most MSI CRC cell lines are more resistant to curcumin, whereas most MSS CRC cell lines are 
sensitive to curcumin.  
On the other hand, IκB was considered as a key inhibitory protein of NF-κB in the NF-κB signaling 
pathway, and, for the first time, was identified as an important biomarker to predict the sensitivity to 




significantly higher levels of IκB even without treatment, while curcumin-resistant cell lines 
frequently express low IκB levels. 
Interestingly, when combining IκB levels with the MSI status as biomarker for predicting curcumin 
sensitivity, it could correctly distinguish the curcumin sensitive CRC cell lines from curcumin 
resistant CRC cell lines with approximately 72% predictive power. 
4.1 Drawbacks of current chemo-drugs 
Nowadays, Fluorouracil is still the backbone for the treatment of mCRC. And these combinations of 
chemo-drugs have achieved clear improvement of mCRC patients’ outcome. Establishing a 
chemotherapy regimen of fluorouracil combined with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) 
or even these three chemo-drug combinations (FOLFOXIRI) is a treatment regimen that can produce 
better anti-tumor effect [158-162].  
However, these treatment modalities are usually accompanied with major side effects. As Katona et 
al. [163] reported, 5-FU as the standard treatment care for CRC, however, its efficacy is limited due 
to toxic side effects, such as mucositis, diarrhea, myelotoxicity, angina pectoris, hypertension. 
In addition, the oxaliplatin chemotherapy was also regarded as classical first line chemo-drug for 
CRC treatment. However, the main drawback of the addition of oxaliplatin chemotherapy is the 
development of cumulative sensory neuropathy [164-166]. Besides, more cases have been reported 
that patients with CRC are hypersensitive to oxaliplatin, and even if it rarely occurs, it is considered 




One more first-line chemo-drug for CRC treatments, irinotecan is also accompanied by severe 
toxicities, such as neutropenia and diarrhea which can lead to interruption or cessation, thereby, 
jeopardizing prognosis and life quality of CRC patients [169]. Cardiotoxicity is frequently seen in 
CRC patients treated with chemo-drugs, such as 5-FU, capecitabine [170, 171], capecitabine in 
conjunction with oxaliplatin [172] as well as FOLFOX [173, 174]. 
Although, a large number of clinical trials have benefited from combination therapy, in terms of the 
overall quality of life of patients, multi-drug combinations are still unsatisfactory due to aggravated 
side effects. As Montagnani et al. reported, FOLFOXIRI confers significant benefit in 
progression-free survival, overall survival, response and R0 resection rates but is more toxic 
compared with FOLFIRI [175]. 
Moreover, chemo-drug resistance was still an additional major challenge in the clinical treatment for 
advanced CRC patients as a remarkable progress in tumors [176-180]. However, the mechanism for 
chemotherapy resistance is not fully known. Gong et al. [181] reported that Nuclear 
factor-carotenoid 2-related factor 2 (Nrf2), a main regulator of cells against oxidative and 
electrophilic stress, is considered to be the possible factor for 5-FU resistance. In addition, a recent 
study reported that 5-FU resistance is associated with the transcriptional coactivator YAP [182]. In a 
linear model for predicting chemotherapy resistance and survival rate, the eight-lncRNA signature is 
defined as a new biomarker for predicting FOLFOX chemotherapy response and prognosis of 
patients with mCRC [183]. In the exploration of oxaliplatin resistance, Lan et al. [184] found that 
tumor-associated macrophages possibly promote resistance of drug via METTL3-mediated m6 A of 




The KRAS, NRAS, and BRAF mutation status of patients with mCRC is the most important 
determinant of cetuximab resistance. The data analysis showed that all mCRC patients with BRAF 
mutations or multiple mutation patterns were cetuximab non-responders. A mutation in one of KRAS, 
NRAS, and BRAF was significantly associated with poorer response rate (7.1%) as well as 
progression-free survival (8.0 months) when compared to all Ras wild-type mCRC patients (74.4% 
and 11.6 months) [185]. Roock et al. [186] further confirmed that BRAF, NRAS, and additional 
PIK3CA exon 20 mutations are significantly associated with a low response rate to cetuximab.  
Not only mentioned above, a majority of researchers are dedicating to overcoming or reducing drug 
resistance in the chemotherapy of CRC. In short, they try to predict the biomarkers leading to 
chemo-drug resistance or they screen a specific subset of CRC with high sensitivity or resistance to a 
certain chemo-drug or multiple chemo-drug combinations.  
However, to date, these issues in chemotherapy including toxic side effects and drug resistance, still 
are known as a very challenging problem limiting the efficacy of therapies and impacting the CRC 
patient's quality of life [187]. Therefore, more effective treatments are mandatory. Among others, 
this has triggered for the scientific exploration of natural compounds with anti-cancer properties 
which possess fewer side effects.  
4.2 Safety and effectiveness of curcumin 
As mentioned before, curcumin, one such diet-derived agent, is expected to become a promising 
candidate for drug use. In terms of safety, few toxicities have been reported in previous clinical 




and clinical populations [188]. A study of curcumin dose escalation (standard powder extract and 
uniformly ground, C3 Complextrade trademark, Sabinsa Corporation) was conducted to evaluate the 
maximum tolerated dose and safety of a single dose [189]. In this study, 24 healthy volunteers were 
included and administered increasing doses from 500 to 12,000mg. 7/24 experienced only a very 
mild toxicity which was not associated with the increased dose of curcumin. The tolerance and safety 
of curcumin in high single oral dose application appears to be excellent, even at very high doses such 
as 12g/day in humans [189]. Moreover, window of opportunity studies for CRC patients have 
determined both safety and tolerance for patients awaiting surgical resection of cancer [132, 190]. 
After oral administration, pharmacologically active concentrations of curcumin are detectable in 
blood and bowel mucosa [132]. This phase I clinical trial of oral curcumin included 15 patients with 
advanced CRC refractory to standard chemotherapies. These patients consumed curcumin doses 
between 0.45 and 3.6g daily for up to 4 months, and the biological activity was detectable. The study 
suggested that curcuma extract can be administered safely to patients with advanced CRC at doses of 
up to 2.2g daily [132]. 
The potential of curcumin as a low toxicity adjuvant for chemotherapy has also been studied in 
preclinical models for CRC treatment [188]. The powerful activity of curcumin as well as novel 
curcumin in cancer has been completed in phase I clinical trials involving efficacy and systemic 
circulation, and initiated the ongoing phase II and phase III clinical trials in multiple centers of 
research around the world [132, 191-194]. 
In terms of effectiveness, the present study determined curcumin’s efficacy in decreasing cell 




is most possibly linked to the NF-κB pathway. Furthermore, a lot of supportive studies also have 
illustrated the effectiveness of curcumin in vivo [135, 195-197] and in patient-derived ex vivo models 
[198, 199] . 
It is worth noting that chemo-drugs combined with curcumin have an additive or synergistic effect 
on CRC patients and are a well-tolerated chemotherapy adjunct. James et al. [198] reported, that 
curcumin alone and curcumin in combination with oxaliplatin / 5-FU significantly decreased the 
spheroid number in cancer stem cell (CSC) models of patient-derived CRC liver metastases and the 
number of cells with high aldehyde dehydrogenase activity. Furthermore, adding curcumin to 
oxaliplatin / 5-FU can increase the anti-proliferation and pro-apoptosis effects for these CRC 
patient-derived explants. In phase I clinical trials, a dose escalation study revealed curcumin is a safe 
and tolerable adjunct to FOLFOX chemotherapy in patients with CRC liver metastases [198]. 
Several similar studies also showed that curcumin significantly induced apoptosis and decreased 
proliferation when combined with oxaliplatin in CRC cell lines [200] and in vivo using a HCT116 
xenograft mouse model [135]. In a phase IIa open-labelled randomized controlled trial, Howells et al. 
[188] evaluated the safety, efficacy, survival outcome, neurotoxicity and plasma curcuminoids level 
in patients with a histological diagnosis of mCRC treated by folinic acid + 5-fluorouracil + 
oxaliplatin (FOLFOX) or by FOLFOX + oral curcumin (CUFOX). 28 patients with mCRC were 
randomly divided into two groups receiving either FOLFOX or CUFOX chemotherapy. This study 
[188] firstly determined the safety and tolerance of addition of daily oral curcumin to FOLFOX. 
More than 1.00pmol/ml curcumin glucuronide could be detected in 15/18 cases receiving CUFOX. 




significantly better overall survival (FOLFOX vs. CUFOX; 200d vs. 502d, respectively). Meanwhile, 
no significant difference was observed concerning neurotoxicity as well as other toxic side effects 
[188]. 
These clinical trials determined that mCRC have a greater sensitivity to the combination of curcumin 
with chemotherapy. Combination therapy of curcumin and FOLFOX is indisputable for improving 
the survival benefits in patients with advanced CRC. Regarding the future, curcumin might become a 
promising chemotherapy under development for the mCRC treatment and comprehensive profiles 
are also currently being evaluated in most clinical trials. 
4.3 Improved absorption efficacy of curcumin 
4.3.1 Improvement of curcumin bioavailability 
Although an increasing number of studies have predicted that curcumin will become an effective 
anticancer candidate drug, it is poorly absorbed and has low bioavailability, which limits its clinical 
transformation [201]. To overcome this challenging issue in the clinical application of curcumin, a 
series of innovative forms of curcumin were developed aiming to improve the absorption and 
achieve better therapeutic effects.  
Among these, Theracurmin® was made using a microparticle and surface-controlled drug delivery 
system, which exhibited more than 40-fold greater bioavailability compared to that of curcumin 
powder in rats [202]. Then, 30mg Theracurmin® or curcumin powder was orally administered in 




that of curcumin powder [202]. In addition, Kanai et al. demonstrated in a controlled clinical trial 
study that Theracurmin® can safely increase high plasma curcumin levels (up to 210mg) without 
saturating the absorption system in healthy volunteers [203]. Hence, Theracurmin® could be 
considered as an advanced tool for further exploring the utility for CRC in clinical trials. A phase I 
study by Kanai’s group has further demonstrated the safety of Theracurmin® in cancer patients [193]. 
In addition, several preclinical studies also reported that Theracurmin® efficiently inhibits the cell 
growth, induces cell death, induces cell cycle arrest in human prostate and bladder [204] as well as in 
pancreatic cancer [205]. However, until now, the clinical applicability of Theracurmin® for patients 
with CRC remains unclear. 
In addition, nanocurcumin preparations, such as liposomal curcumin (Lipocurc™) and lecithinized 
curcumin delivery system (Meriva®), have achieved an advanced bioavailability for curcumin [135, 
206-208].  
In a phase I, single-center, open-label study [209], 32 cancer patients were included and divided into 
two groups. One group of them (n = 26) was treated by an escalated dose from 100 to 300mg/m2 for 
over 8h; no dose-limiting toxicity was observed. Another group (n = 6) received 300mg/m2 
liposomal curcumin infusion for over 6h. Among these cancer patients, one case developed 
hemolysis; three cases had hemoglobin decrease, but no signs of hemolysis and two patients revealed 
significant tumor marker responses and transient clinical benefit. Hence, 300mg/m2 liposomal 
curcumin infusion for 6h is recommended as a starting dose for those heavily pretreated cancer 




following intravenous infusion of Lipocurc™, the plasma curcumin level in cancer patients rose to a 
greater extent with increasing infusion rate compared to healthy individuals [206].  
Another promising nanocurcumin preparation, Meriva® has shown a remarkably higher absorption 
of curcumin at doses significantly lower than unformulated curcumin [210]. This point was further 
supported by a controlled clinical trial [208]. In detail, Belcaro et al. [208] recruited 160 cancer 
patients undergoing chemo- and radiotherapy following surgery. Then, Meriva® was used to assess 
the efficacy in alleviating the side effects in both cases of treatment. The results showed that 
Meriva® may reduce the burden of side effects related to chemo- and radio-therapy, which indicates 
that the application of various preparations of curcumin as a support agent for cancer treatment is 
worthy of systematic research in larger sample clinical trials [208].   
4.3.2 Improvement of curcumin specificity 
4.3.2.1 Curcumin sensitivity and MSI status  
Improving curcumin bioavailability should not only promote absorption as describe above, but also 
depend on tumor-specific and patient-specific factors. In the present study, most CRC cell lines with 
the molecular type of MSS or high IκB level were more sensitive to curcumin, but 9/11 CRC cell 
lines with the characteristics of MSI and low IκB level were strongly resistant to curcumin. 
Similarly, Shakibaei et al. [157] reported that curcumin combined with 5-FU could impact 
MMR-deficient CRC cells, however was more sensitive to MMR-proficient CRC cells. Moreover, in 




characterized by MSS and D.L. Dexter 1 (DLD-1) characterized by MSI [211], were used for 
evaluating the sensitivity to combination of curcumin and resveratrol. The results showed that IC50 
values of curcumin and resveratrol were 71.8μM (20.5μM curcumin + 51.3μM resveratrol) for the 
DLD-1 cell line, but a relatively lower value of 66.21μM (18.9μM curcumin + 47.3μM resveratrol) 
for the Caco-2 cell line, respectively [212].  
However, Majumdar et al. reported an opposite result, with a better effect shown in HCT116 (MSI) 
after treatment with curcumin and resveratrol, but not in HT29 characterized as MSS [213]. 
Moreover, Jiang et al. presented that the MMR system is strongly associated with the cellular 
response to curcumin in human hereditary non-polyposis CRC [214]. A heightened cytotoxic 
response to curcumin was observed in MMR-deficient CRC cell lines (MLH1-deficient cell lines: 
HCT116+ch2 and RKO; MSH2-deficient CRC cell line: Hec59) compared with matched 
MMR-proficient cell lines (MLH-proficient CRC cell lines: HCT116+ch3 and RKO+MLH1+; 
MSH2-proficient CRC cell line: Hec59 +ch2). As a result, these findings proposed that curcumin 
might be more specific for MSI cancers. In addition, the MSI-negative cancers may show a good 
response to the combination treatment of curcumin and Chk1 inhibitors [214]. In 2016, they reported 
that CRC cell lines harboring mutations in MMR exhibited higher sensitivity to curcumin as a result 
of durable unrepaired DNA damage induced by curcumin. Their study further presented that 
GADD45α modulates curcumin sensitivity through a mechanism involving c-Abl tyrosine 
kinase-mediated activation of c-Jun N-terminal kinase in a MMR-dependent manner [215, 216].  
Moreover, Wei et al. [217] displayed a potent apoptosis-inducing ability of curcumin on 




proper control groups with the feature of sufficient MMR, thus, this cannot conclude higher 
sensitivity in MMR-deficient CRC cell lines without comparison.  
In an exploration of the underlying mechanism, Aussem et al. showed that nutritional Nrf2 activators 
(such as sulforaphane, curcumin, quercetin, resveratrol) have the potential to activate the cellular 
anti-oxidative system. And patients with lynch syndrome alteration have a high risk of cellular 
carcinogenesis caused by oxidative stress. Therefore, this study hypothesized that nutritional Nrf2 
activators may have the potential to reduce the risk of cancer in lynch patients by modulating 
oxidative stress and inflammation [218]. 
Firstly, this present data is supportive for the point as far as curcumin could decrease cell viability of 
all 32 CRC cell lines with the characteristics of not only MSI, but also MSS. Also, a higher cell death 
was observed in both MSI and MSS cell lines at the high treatment dose of 20μM. However, 
constantly and repeatedly, the majority of MSS CRC cell lines were found more susceptible to 
curcumin, whereas a response to curcumin was observed for most MSI CRC cell lines only for very 
high concentrations of 20μM or 25μM. The IC50 for two MSS CRC cell lines (HROC18 and 
HROC357) were as low as 6.69μM and 6.97μM, respectively. However, close to 3-fold higher IC50 
of curcumin were found in the MSI CRC cell lines HROC24 and HROC285. In order to exclude the 
potential bias of individuality, especially in the light of the above mentioned studies with the 
opposite findings that curcumin-sensitive CRC cell lines were mostly MMR deficient, analyzing a 
larger number of CRC cell lines (n = 32) from patients or PDX models where clinical and tumor 




passage number 50, and thus can still be considered as suited to closely mirror the clinical behavior 
and biology of the original patients’ tumors. 
4.3.2.2 Curcumin sensitivity and IκB level in CRC cells  
Mechanistically, the NF-κB signaling pathway is well known to represent the classical pathway 
responsible for the anti-cancer action of curcumin. This present work could identify the NF-κB 
inhibitor, IκB as a potent biomarker for predicting curcumin-sensitivity of CRC cell lines.  
A study from Sandur et al. [130] described that most patients becoming resistant to radiation therapy 
due to an activation of the NF-κB pathway. Thus, to overcome this issue, one possible way is to 
stimulate the inhibitors of these pathways, accordingly, making these tumors sensitive to 
radiotherapy again. They could prove this expectation that albeit radiation activated the NF-κB 
signaling pathway and thus led to resistance of therapy, curcumin treatment could reverse this 
radio-resistance by suppressing the radiation-induced NF-κB activation. In more detail, the elevation 
of NF-κB signaling induced by radiotherapy was mediated by stimulating Akt phosphorylation, 
inhibitor of κB kinase (IKK) activation as well as IκBα phosphorylation. Moreover, curcumin also 
inhibited NF-κB-regulated gene products, such as Bcl-2, Bcl-x(L), inhibitor of apoptosis protein-2, 
cyclooxygenase-2 and cyclin D1.  
Similarly, Shakibaei et al. [129] also reported that curcumin could reverse 5-FU treatment resistance. 
Curcumin enhanced 5-FU-induced expression of pro-apoptosis proteins (caspase-3, caspase-8, 
caspase-9, PARP and Bax), and on the other hand, weakened the anti-apoptosis proteins such as, 




down-regulation of the signaling by curcumin is mainly through suppressing the IKK activation and 
IκB alpha phosphorylation [129]. 
De-regulation of NF-κB as well as inhibition of its downstream targets has been proposed as an 
important targetable mechanism of CRC resistance to therapy [219]. IκB alpha was considered as a 
key protein to reverse the chemotherapy induced up-regulated NF-κB signaling pathway. This was 
explained by curcumin inhibiting the oxaliplatin-induced activation of NF-κB and decreasing the 
expression of NF-κB anti-apoptotic and pro-proliferative gene products. Different gene expression 
patterns were shown in oxaliplatin-resistant and -sensitive CRC cell lines after combination 
treatment of curcumin and oxaliplatin. As compared to oxaliplatin-sensitive CRC cells, curcumin 
more extensively inhibited the NF-κB level in oxaliplatin-resistant cell line [128].  
Similar results were also obtained in the present study, as I measured increasing IκB levels in 
response to curcumin treatment in six CRC cell lines including three curcumin-sensitive and three 
-resistant ones, respectively. Compared to curcumin-resistant CRC cell lines, the curcumin-sensitive 
CRC cell lines showed very higher IκB levels at the same curcumin concentration. Taken together, 
experimental evidence has proven that curcumin treatment is associated with inhibition of NF-κB, 
activation of IκB alpha, suppression of IκB alpha phosphorylation as well as down-regulation of 
NF-κB related anti-apoptotic and cell proliferation proteins [220-222]. In the present study, IκB 
alpha was identified as an important biomarker to predict the curcumin sensitivity of CRC cell lines. 




NF-κB transcription factors consist of five homologous subunits including RelA/p65, c-Rel, RelB, 
p50/NF-κB1, and p52/NF-κB2, which dimerize with the IκBs and are retained in the cytoplasm [223, 
224]. The IKK complex is immediately upstream of the IκB-bound NF-κB dimer. It consists of two 
catalytic subunits (IKKα and IKKβ) and one regulatory subunit (IKKγ/NEMO) [225, 226]. When the 
IKK complex is activated through several cell stimulation pathways, IκB is phosphorylated and 
thereby targeted for ubiquitination and degradation by the 26S proteosome. Furthermore, the released 
NF-κB travels to the nucleus and participates in transcriptional programs [227]. 
Briefly, there are two NF-κB activation signaling pathways named canonical and non-canonical 
pathway [223] (Figure 21). The non-canonical NF-κB activation is associated with lymphoid 
organogenesis via activation of NF-κB-inducing kinase (NIK) [228-230], whereas the canonical 
NF-κB activation depends on IKK activation, nuclear localization of RelA/P50 dimers, IκB 
phosphorylation or degradation. And it has been proved that high RelA/p65 expression is correlated 
with increased expression of NF-κB target genes. Both of them, but even more the classical NF-κB 
activation pathway are crucial for progression of carcinomas [230-236].  
In sum, enhanced degradation of IκB directly contributes to the activation of NF-κB and impacts the 
tumor cell proliferation, apoptosis, cell cycle and migration as well as invasion. In addition, 
curcumin has been found to mediate its anti-tumor activity by down-regulation of NF-κB via IκB 
activation. Thus, IκB as biomarker can likely predict the curcumin sensitivity of CRC cell lines. A 
significant correlation between IC50 of curcumin and the IκB level was presented in CRC cell lines 
measured before any treatment. It is worthy to pronounce that the cell viability is strongly associated 






Figure 21. The two main signaling pathways of NF-κB activation [226]. 
In addition, a growing number of studies showed that NF-κB activation is correlated with 
interleukin-6 (IL-6) [105, 237-241] and (interleukin-8) IL-8 [241-244] (Figure 22). Pre-treatment 
with curcumin effectively suppressed NF-κB activation coinciding with a decreased amount of IL-6 
and IL-8, which also demonstrated the key role of the NF-κB pathway in augmenting expression of 




mRNA as well as protein levels were significantly down-regulated by curcumin in vivo. They 
additionally observed that curcumin reduced the NF-κB binding elements of TNF-α and IL-6 
promoters. This study thus suggested that it might be an interesting long-term effect of curcumin to 
reduce cancer progression via down-regulation of TNF-α and IL-6. However, since I did not measure 
IL-6 and IL-8 secretion of the CRC cell lines included into this study, they used a potential additional 
biomarker for curcumin sensitivity can only be speculated on. 
 




4.3.3 MSI status and IκB level in CRC cells  
In the present study, I defined two possible biomarkers (MSI status and IκB level in CRC cells) 
which are predicting curcumin sensitivity of CRC cell lines. Surprisingly, a higher level of IκB was 
seen in MSS, but not in MSI CRC cells. When combining the MSI status with the IκB level as 
biomarkers, a significant and strong prediction ability could be demonstrated. The present study is 
the first to report on the curcumin sensitivity of mostly MSS CRC cells with higher IκB levels, but 
resistance in mostly MSI CRC cells with lower IκB level. These findings are somehow opposing the 
data from some previous studies [213, 214, 217, 246]. 
However, since my data have been obtained with a relatively high number of low-passaged cell lines, 
even allowing for statistical comparison, they can be considered as relevant. Concerning the data 
from Wei [217], Majumdar [213] Jiang [214] Fonseca [246] and colleagues, one can only speculate 
that a part of the opposite finding might best be explained by the fact that only a limited number of 
classical CRC cell lines has been analyzed and moreover, the focus of their study was not curcumin 
but several drugs. 
In a general analysis of the Raf-1 Kinase Inhibitor Protein (RKIP), Koelzer et al. [247] found that 
RKIP loss significantly predicted for tumor metastasis, vascular invasion, tumor budding as well as 
invasive border configuration. Deficiency of RKIP caused greater NF-κB activation and was more 
frequently observed in MMR-deficient cancers; however, was not linked to mutations in K-RAS and 
B-Raf [247]. It is thus tempting to speculate, that on the one hand, the curcumin sensitive MMR 




curcumin resistant MMR deficient cell lines might have lost or reduced RKIP expression. However, 
this needs to be analyzed in another study. 
Moreover, the alkylating agent temozolomide influences malignant glioma as a result of cellular 
cytotoxicity by forming O (6)-methylguanine adducts. And effectiveness of temozolomide is 
consistent with inhibition of NF-κB activity, also inhibits NF-κB activation by TNF as well as other 
inducers (lipopolysaccharide, doxorubicin, and phorbol 12-myristate 13-acetate). It is important to 
mention that the ability of temozolomide for inhibition of NF-κB activation is in the presence of a 
functioning MMR system. Whereby, their work showed that temozolomide leads to inhibition of 
NF-κB activity and explained a correlation between MMR processing of alkylator-induced DNA 
damage and cell apoptosis [248]. Based on these data, and in line with the RKIP-loss data discussed 
above [247] high NF-κB activation seems to be associated with a deficient MMR system. These 
findings are also matching my results concerning NF-κB activation mostly in MMR deficient HROC 
cell lines. In addition, Chen et al. [249] evaluated the effect of curcumin on MMR proteins (hMSH2 
and hMLH1) after ultraviolet (UV) irradiation of leukemic cells. The expression of hMSH2 and 
hMLH1 genes was not influenced by UV irradiation alone, but significantly increased when UV 
irradiation was combined with a curcumin treatment. Moreover, this combination treatment also 
induced cell apoptosis. The latter can best be explained by the dual role of the MMR system – either 
repair mismatched DNA or, when this fails, induce cellular apoptosis [249]. These data might also 
explain why curcumin acted more effectively on MMR proficient HROC cell lines. 
Opposite to these findings, Fonseca and colleagues [246] evaluated the correlation between MMR 




carcinoma [246]. There was a significant correlation between the expression of NF-κB and hMSH2 
(rs = 0.570, P < 0.001) as well as hMSH6 (rs = 0.658, P < 0.001). They concluded that activating the 
transcription of NF-κB (inflammatory principle) in turn activates the DNA repair system (hMSH2 
and hMSH6); a hypothesis which at least could explain the involvement of the inflammatory 
component in the MMR system. Thus, modulating the expression of NF-κB may be essential for the 
control of neoplasia, ageing of cells, and above all cell survival in important tissues and organs. 
Alcohol consumption and smoking have a remarkable influence on the DNA repair system in oral 
squamous cell carcinoma [246]. However, the 28 samples have not been stratified into MMR 
proficient or deficient.  
In sum, data of different studies indicated that the response to curcumin of cancer, and especially 
CRC cells, is mediated by inhibition of NF-κB by IκB, and seems to additionally be linked to the 





5. Conclusions  
CRC still is a big burden worldwide with a still unsatisfying survival rate, especially for patients 
having distant metastases. Currently, chemotherapeutic and also novel drugs have significantly 
improved patients’ survival, but there are two major issues of side effects and the development of 
drug resistance. Therefore, natural products like curcumin with proven antitumoral action are under 
research as promising candidates to contribute to anti-tumor treatment.  
This present study could demonstrate that curcumin can inhibit CRC cell viability, induce cell 
apoptosis, suppress cell migration and invasion as well as induce cell cycle arrest at the G2/M stage 
in vitro. The 32 CRC cell lines analyzed respond to curcumin to a different extent. The focus was 
primarily to identify the subset of cell lines showing high curcumin sensitivity, to unravel common 
features of the responding cell lines in order to identify possible biomarkers which could 
subsequently be used to predict response to curcumin. Most curcumin-sensitive CRC cell lines have 
the following characteristics: molecular type of MSS and/or higher IκB expression level of the cells 
before any curcumin treatment. Whereas the curcumin-resistant CRC cell lines were MSI and had 
low cellular IκB levels. The predictive ability of this biomarker combination was statistically 
significant with a predictive power of around 72% in a classical ROC/AUC analysis. 
In sum, these data support the ongoing activities to improve the bioavailability of curcumin since its 
clinical application is limited until the bioavailability is largely improved. With the help of a large 
panel of patient-derived low passaged CRC cell models with known sensitivity and predictive 




HROC model collection also includes a high number of matching PDX in vivo models, the complete 
preclinical drug testing can even be envisioned.  
With the data obtained so far, I suggest that MSS patients with high IκB expression level can be 
expected to benefit from a clinical treatment by improved curcumin versions. Further studies should 
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15-PGDH 15-prostaglandin dehydrogenase 
AUC Area under the ROC curve 
BDMC Bisdemethoxycurcumin 
CC Colon cancer 
CIMP CpG island methylator phenotype 
CIN Chromosomal instability 
COX-2 Cyclooxygenase 2 
CRC Colorectal cancer 
CSC Cancer stem cell 
DLD-1 D.L. Dexter 1 
DMC Demethoxycurcumin 
EGFR Epidermal growth factor receptor 
Egr-1 Early growth response protein 1 
FOLFIRI Fluorouracil combined with irinotecan 
FOLFOX Fluorouracil combined with oxaliplatin 
FOLFOXIRI Combinations of fluorouracil, oxaliplatin and irinotecan 
IKK Inhibitor of κB kinase 
IL-6 Interleukin-6 
IL-8 Interleukin-8 
IκB Inhibitors of NF-kappa-B 
MAPK Mitogen-activated protein kinase 




mCRC Metastatic colorectal cancer 
MLH1 MutL homolog 1 
MMR Mismatch repair 
MSH2 MutS homolog 2 
MSH6 MutS homolog 6 
MSI Microsatellite instability 
MSS Microsatellite stability 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NIK NF-κB-inducing kinase 
Nrf2 Nuclear factor-carotenoid 2-related factor 2 
RC Rectum cancer 
RKIP Raf-1 Kinase Inhibitor Protein 
ROC Receiver Operating Characteristic 
ROS Reactive oxygen species 
TGF-β Transforming growth factor-β 
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Figure 1. Estimated number of new cancer cases for both sexes and all ages in 2020, worldwide (A); 
Estimated number of deaths from cancers for both sexes and all ages in 2020, worldwide (B).  
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ages in 2020, worldwide.  
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APC (A), K-Ras (B), B-Raf (C), PIK3CA (D), TP53 (E) and ATM (F).  
Figure 14. The comparison of IC50 of curcumin between MSI and MSS CRC cell lines (A). The 




Figure 15. The IκB level in CRC cells and their MSI status were used to predict the CRC cell lines 
sensitivity to curcumin.  
Figure 16. The cell death was measured in three curcumin-resistance CRC cell lines and three 
curcumin-sensitivity CRC cell lines after treating with 10μM, 15μM, 20μM curcumin.  
Figure 17. Migration test in two curcumin-resistant CRC cell lines and two curcumin-sensitive CRC 
cell lines treated by 10μM curcumin. 
Figure 18. Cell cycle in two curcumin-resistant CRC cell lines and two curcumin-sensitive CRC cell 
lines treated by 10μM, 15μM, 20μM curcumin.  
Figure 19. The IκB level in three curcumin-resistant and three curcumin-sensitive CRC cell lines 
treated by 10μM, 15μM, 20μM curcumin. 
Figure 20. Correlation analysis of cell viability and IκB after treatment with 10μM (A), 15μM (B) 
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Figure 21. The two main signaling pathways of NF-κB activation. 
Figure 22. Targeting potential NFκB contributors to carcinogenesis. 
7.3 Table list 
Table 1. Summary of ongoing clinical trials with bioavailable curcumin formulations in CRC. 






8. Thesis statements 
⚫ Curcumin’s clinical application has been found to be restricted by its poor bioavailability. 
However, novel drug formulations currently under research suggest that a “revival” of this very 
old natural compound seems possible also for oncological purposes. 
⚫ Curcumin inhibits cell proliferation, accelerates cell apoptosis, induces cell cycle arrest in G2/M 
stage as well as suppresses cell migration and invasion in colorectal cancer (CRC) cell lines. 
⚫ The sensitivities to curcumin of the 32 CRC patient-derived cell lines tested are highly 
individual. 
⚫  Mutations of the frequently mutated genes in CRC: APC, K-Ras, B-Raf, PIK3CA, TP53 and 
ATM were found to be not related to curcumin sensitivity or resistance in CRC cells.  
⚫ Most microsatellite instable (MSI) CRC cell lines are resistant to curcumin, whereas most 
microsatellite stable (MSS) CRC cell lines are sensitive to curcumin. 
⚫ Curcumin-sensitive cell lines express significantly higher levels of inhibitors of NF-kappa-B 
(IκB), while curcumin-resistant cell lines frequently express low IκB levels. IκB levels 
dramatically rise with increasing concentrations of curcumin.  
⚫ There is a significant difference between the IκB expression level in MSS (high) compared to 
MSI (low) CRC cell lines.  
⚫ The combined biomarkers microsatellite status and IκB expression level predict the curcumin 
sensitivity of a CRC cell line to 72%. 
⚫ When considering that MSS CRC cases hardly benefit from the novel immunotherapeutic 
treatment options, the fact that they are more sensitive to curcumin is of potential clinical 
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